Journal article

A Randomized, Placebo-Controlled Trial of Pentoxifylline on Erythropoiesis-Stimulating Agent Hyporesponsiveness in Anemic Patients With CKD: The Handling Erythropoietin Resistance With Oxpentifylline (HERO) Trial

David W Johnson, Elaine M Pascoe, Sunil V Badve, Kim Dalziel, Alan Cass, Philip Clarke, Paolo Ferrari, Stephen P McDonald, Alicia T Morrish, Eugenie Pedagogos, Vlado Perkovic, Donna Reidlinger, Anish Scaria, Rowan Walker, Liza A Vergara, Carmel M Hawley

American Journal of Kidney Diseases | W B SAUNDERS CO-ELSEVIER INC | Published : 2015

Grants

Funding Acknowledgements

Dr Johnson has previously received consultancy fees from Sanofi-Aventis and consultancy fees, speakers' honoraria, research grants, and travel sponsorships from Amgen, Roche, and Janssen-Cilag. He was the recipient of a RoFAR grant, which partly funded the HERO trial, and a Queensland Government Health Research Fellowship. Dr Hawley has previously received consultancy fees, speakers' honoraria, research grants, and/or travel sponsorships from Amgen, Roche, and Janssen-Cilag. Dr Cass has previously received consultancy fees, speakers' honoraria, and/or research grants from Amgen, Roche, Baxter, Fresenius, and Merck. Dr Walker has previously received consultancy fees, speakers' honoraria, research grants, and travel sponsorships from Amgen, Roche, and Janssen-Cilag and has served on Advisory Boards for Amgen, Roche, and Janssen-Cilag. The other authors declare that they have no other relevant financial interests.